TRAVERE THERAPEUTICS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$605M
↑+1.9% +$11Mvs FY2024
Total Liabilities
$490M
↓-8.4% -$45Mvs FY2024
Equity
$115M
↑+94.4% +$56Mvs FY2024
Cash
$93M
↑+58.9% +$35Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $605M | $594M |
| Current Assets | $438M | $417M |
| Cash | $93M | $59M |
| ST Investments | $0 | $0 |
| Receivables | $80M | $27M |
| Inventory | $36M | $42M |
| Other Current | $228M | $289M |
| Non-Current Assets | $168M | $177M |
| PPE | $4M | $5M |
| Goodwill | $0 | $800K |
| Intangibles | $114M | $104M |
| Investments | $0 | $0 |
| Other Non-Current | $50M | $67M |
| Total Liab+Eq | $605M | $594M |
| Current Liab. | $160M | $201M |
| Accounts Payable | $25M | $24M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $3M |
| Other CL | $135M | $174M |
| Non-Current Liab. | $330M | $334M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $330M | $334M |
| Equity | $115M | $59M |
| Retained Earnings | $1.47B | $1.45B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · TVTX · Comparing FY2025 vs FY2024